ES2111559T3 - Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico. - Google Patents

Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico.

Info

Publication number
ES2111559T3
ES2111559T3 ES91900636T ES91900636T ES2111559T3 ES 2111559 T3 ES2111559 T3 ES 2111559T3 ES 91900636 T ES91900636 T ES 91900636T ES 91900636 T ES91900636 T ES 91900636T ES 2111559 T3 ES2111559 T3 ES 2111559T3
Authority
ES
Spain
Prior art keywords
retroviruses
infectability
xxxx
infectious
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900636T
Other languages
English (en)
Inventor
Robert J Gorelick
Alan R Rein
Larry O Arthur
Louis E Henderson
Stephen Oroszlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Commerce
Original Assignee
US Department of Health and Human Services
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Commerce filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2111559T3 publication Critical patent/ES2111559T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

ESTA INVENCION DEFINE UN ROL BIOLOGICO PARA LA SIGUIENTE SECUENCIA DE AMINO ACIDOS QUE SE ENCUENTRA EN EL DOMINIO NUCLEOCAPSIDO DE LAS POLIPROTEINAS PRECURSORAS "GAG" DE TODOS LOS RETROVIRUS COMPETENTES DE REPLICA: -CYS-X-X-CIS-X-X-X-X-HIS-X-X-X-X-CIS-, DONDE X REPRESENTA AMINO ACIDOS VARIABLES. LOS RESIDUOS INVARIANTES CONSTITUYEN PARTE DE UNA ESTRUCTURA DE PROTEINA VITAL, AL MENOS UNO DE LOS CUALES SE ENCUENTRA EN TODOS LOS RETROVIRUS Y ESTAN INVOLUCRADOS EN LA SELECCION Y EMPAQUETAMIENTO DE ARN VIRAL GENOMICO EN PARTICULAS DE VIRUS INFECCIOSOS. LA INTERRUPCION DE ESTA ESTRUCTURA LLEVA A LA FORMACION DE PARTICULAS TIPO-VIRUS QUE PARECEN DE ESTRUCTURA NORMAL, PERO QUE NO CONTIENEN EL COMPLEMENTO NORMAL DE ARN VIRAL. SIN EMBARGO, SU INFECTABILIDAD SE REDUCE DRASTICAMENTE O SE ELIMINA COMPLETAMENTE. LA INFECTABILIDAD DE CUALQUIER RETROVIRUS, INCLUYENDO RETROVIRUS HUMANOS, Y MAS PARTICULARMENTE EL VIRUS DE INMUNODEFICIENCIA HUMANA (VIH), SE PUEDE REDUCIR DRASTICAMENTE, O ELIMINAR COMPLETAMENTE GENERANDO MUTANTES QUE CARECEN DE ALGUN O DE TODOS LOS RESIDUOS INVARIANTES REQUERIDOS PARA FORMAR LA ESTRUCTURA. ADEMAS, CUALQUIER MEDIO PARA INTERRUMPIR LAS FUNCIONES DE ESTA RED, A SU VEZ INTERRUMPIRA EL CICLO DE VINA VIRICA. ASI, CON LOS CONOCIMIENTOS PROVISTOS POR ESTA INVENCION, SE PUEDEN IDEAR REACTIVOS QUIMIOTERAPEUTICOS DIRIGIDOS HACIA ESTA RED.
ES91900636T 1989-10-31 1990-10-31 Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico. Expired - Lifetime ES2111559T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42928789A 1989-10-31 1989-10-31

Publications (1)

Publication Number Publication Date
ES2111559T3 true ES2111559T3 (es) 1998-03-16

Family

ID=23702610

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900636T Expired - Lifetime ES2111559T3 (es) 1989-10-31 1990-10-31 Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico.

Country Status (10)

Country Link
EP (1) EP0500791B1 (es)
JP (1) JPH0716420B2 (es)
AT (1) ATE162949T1 (es)
AU (1) AU636755B2 (es)
CA (1) CA2072125C (es)
DE (1) DE69032028T2 (es)
DK (1) DK0500791T3 (es)
ES (1) ES2111559T3 (es)
GR (1) GR3026457T3 (es)
WO (1) WO1991006318A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
US5532154A (en) * 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
EP1011729B1 (en) * 1996-05-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligonucleotides which specifically bind retroviral nucleocapsid proteins
AU2001276752A1 (en) * 2000-08-08 2002-02-18 The Kitasato Institute Virus-like micrograins and process for producing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067778A1 (en) * 1989-10-16 1991-04-17 The Whitehead Institute For Biomedical Research Non-infectious hiv-1 particles and uses therefor

Also Published As

Publication number Publication date
GR3026457T3 (en) 1998-06-30
DE69032028T2 (de) 1998-05-20
EP0500791B1 (en) 1998-02-04
DE69032028D1 (de) 1998-03-12
DK0500791T3 (da) 1998-04-06
CA2072125A1 (en) 1991-05-01
EP0500791A1 (en) 1992-09-02
CA2072125C (en) 2000-05-23
AU636755B2 (en) 1993-05-06
EP0500791A4 (en) 1993-02-10
AU7740291A (en) 1991-05-31
WO1991006318A1 (en) 1991-05-16
JPH04505163A (ja) 1992-09-10
JPH0716420B2 (ja) 1995-03-01
ATE162949T1 (de) 1998-02-15

Similar Documents

Publication Publication Date Title
DE68927025T2 (de) HIV-2-Virusvarianten
DE69624346D1 (de) Verbindung der struktur aminosäure-hydroxyethylamino-sulfonamide als inhibitoren der retroviralen protease
NO921969L (no) Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener
ES2140380T3 (es) Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas.
FR2731013B1 (fr) Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
DE3780016T2 (de) Pharmazeutisches praeparat mit 3'-desoxythymidin-2'-en(3'-desoxy-2',3'-didehydrothymidin) zur behandlung von patienten mit retroviralen infektionen.
ES2111559T3 (es) Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico.
DK0404625T3 (da) Oligonukleotidsekvenser til amplifikation af genomer af retrovirus af HIV-2 og SIV-typen samt deres anvendelser til in vitro-diagnose af infektioner forårsaget af disse virus
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
ES2061495T3 (es) Peptidos relacionados con el virus htlv-iii, anticuerpos para los peptidos, vacunas, inmunizacion activa y pasiva contra el virus del sida y prueba diagnostica para la deteccion serologica del virus del sida.
KR890701738A (ko) 인체면역결핍 비루스 특이성 단백질분해효소와 이들의 합성 및 원형재현 방법
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
ATE103980T1 (de) Das f-protein vom aids-virus enthaltender impfstoff.
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
Williams et al. HIV-1 and HIV-2 antibodies in Nigerian populations with high-and low-risk patterns.
DK135588A (da) Inaktivering af hiv i proteinholdige oploesninger ved hjaelp af phenoler
DE59100308D1 (de) Verwendung von s-adenosylmethionin als mittel gegen virale infektionen durch retroviren.
ITFI930260A1 (it) Processo per l'estrazione e purificazione dell'alfal-antitripsina (alfal-pi)dalla frazione iv-1 di cohn.
DE68925191D1 (de) Peptide mit schutzeigenschaften gegen ein pathogenes virus des hiv-typs in sensitiven zellen
HUP9904262A2 (hu) Fehérjék alkalmazása retrovírus elleni szerként
ES2163028T3 (es) Composiciones y metodos para detectar y tratar el sindrome de la inmunodeficiencia adquirida.
Hitchcock Molecular localization of conformation-dependent B cell epitopes of the major core protein (p24) of human immunodeficiency virus
FR2829505B1 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
CL2004001413A1 (es) PEPTIDOS QUE CORRESPONDEN A LOS AMINOACIDOS 635 A 673 DE LA PROTEINA TRANSMEMBRANICA gp41 DEL VIH QUE PRESENTAN ACTIVIDAD ANTI-RETROVIRAL.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 500791

Country of ref document: ES